Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
– Preclinical data to highlight potential of LAIR1 blockade in reversing T-cell and myeloid immunosuppression mediated by collagen –
PALO ALTO, CA, November 9, 2021 / Business Wire / -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that the Company will present a scientific poster at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021) being held November 10-14, 2021, in Washington, D.C., USA.
The poster will feature key preclinical data demonstrating the therapeutic potential of anti-LAIR1 antagonistic antibodies as immune checkpoint inhibitor therapy for solid tumors. LAIR1 (Leukocyte Associated Immunoglobulin-like Receptor 1) is an immune inhibitory transmembrane glycoprotein expressed on lymphocytes and myeloid cells and is activated by collagen and other ligands. Collagen is highly abundant in the stroma of many solid tumor types and thought to contribute to immune suppression. The data being presented suggest that LAIR1 blockade could potentially reverse collagen-mediated myeloid cell tolerogenic phenotype and T-cell suppression, thereby promoting a pro-inflammatory solid tumor microenvironment.
Presentation Details
Poster Title:
Antagonistic Antibodies Targeting LAIR1 Enhance T Lymphocyte Activation and Promote Inflammatory Phenotypes in Myeloid Cells
Abstract ID: 304
Presenter: Tao Huang, PhD, Director of Preclinical Development at Immune-Onc Therapeutics
Category: Checkpoint Blockade Therapy
Date: Saturday, Nov. 13, 2021
Time: 7:00 am – 8:30 pm EST
Location: Poster Hall at the Walter E. Washington Convention Center, D.C.
Poster presentations will be accessible in person and virtually. The poster will also be made available on the "Publications & Abstracts" section of the Company's website.
ABOUT IMMUNE-ONC THERAPEUTICS, INC.
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment.
Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development, including IO-108 in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for the treatment of acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). The company also plans to evaluate IO-202 in solid tumors in 1H2022. The U.S. Food and Drug Administration granted IO-202 Orphan Drug Designation for treatment of AML in October 2020. Additional assets in Immune-Onc’s pipeline include IO-106, a first-in-class anti-LAIR1 antibody, and multiple undisclosed programs for solid tumors and hematologic malignancies.
The company has strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center, and has invested in proprietary models, assays, and tools to interrogate the biology and translate this cutting-edge research into the development of novel therapies. Immune-Onc has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and a strategic investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP®). Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit www.immune-onc.com and follow us on Twitter and LinkedIn.
MEDIA CONTACT
Tara Cooper
The Grace Communication Group
tara@gracegroup.us
media@immuneonc.com
650-303-7306